logo.png
Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19
September 10, 2021 06:30 ET | Adagio Therapeutics, Inc.
WALTHAM, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based...
logo.png
Adagio Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
September 01, 2021 06:30 ET | Adagio Therapeutics, Inc.
WALTHAM, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
logo.png
Adagio Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 10, 2021 16:22 ET | Adagio Therapeutics, Inc.
WALTHAM, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based...